Evaluation of Exhaled Breath Condensate Biomarkers in Adults with Combined Allergic Rhinitis and Asthma Syndrome CARAS

What this Trial Is About

Researchers are investigating the differences in biomarker expression in various sample types between healthy individuals and different subgroups of Combined Allergic Rhinitis and Asthma Syndrome CARAS. The study aims to identify potential biomarkers using a simple, direct, and objective approach, focusing on those identifiable by Chinese medicine symptoms and disease stages to support personalized diagnosis and treatment. This observational study is sponsored by Henan University of Traditional Chinese Medicine and involves adults aged 18 to 80 years. Participants are divided into several groups based on disease status, including acute exacerbation CARAS, chronic persistence CARAS, clinical control CARAS, acute exacerbation bronchial asthma BA, chronic persistence BA, clinical control BA, intermittent allergic rhinitis AR, persistent AR, and healthy individuals. No interventions are performed instead, relevant patient information, blood samples, and exhaled breath condensate are collected. Subjects also complete questionnaire surveys as part of data collection. During the study, participants provide blood and exhaled breath condensate samples and complete questionnaires to assess various biomarkers such as interleukin-2 variants, interferon-gamma, tumor necrosis factor-beta, eosinophil cationic proteins, and immunoglobulin E at baseline. Secondary measures include fractional exhaled nitric oxide, lung function tests like forced expiratory volume in one second and forced vital capacity. The study monitors these markers to better understand CARAS, with participation lasting until May 30, 2025.

Exhaled Breath Condensate Biomarkers in CARAS